Facebook Twitter LinkedIn Google Plus RSS

Nymox enrolls patients for new study

By ,

Hasbrouck Heights-based Nymox Pharmaceutical Corp. announced it has enrolled the first patient in a company study of the safety and efficacy of NX-1207 reinjection for the treatment of prostate enlargement, according to a release.

The new study will enroll 100 to 200 patients who had previously participated in an NX-1207 study. The use of NX-1207 for the treatment of moderate to severe prostate enlargement is being evaluated in five Phase 3 trials. NX-1207 is injected by a urologist under ultrasound guidance directly into the area of the prostate to be treated in an in-clinic procedure that takes only a few minutes and does not require catheterization, anesthetics or sedation.

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!